Locoregional recurrence in patients with HER2 positive breast cancer

Janaina Brollo, Maximiliano Cassilha Kneubil, Edoardo Botteri, Nicole Rotmensz, Bruno Achutti Duso, Luca Fumagalli, Marzia Adelia Locatelli, Carmen Criscitiello, Visnu Lohsiriwat, Aron Goldhirsch, Maria Cristina Leonardi, Roberto Orecchia, Giuseppe Curigliano

Research output: Contribution to journalArticlepeer-review


Literature shows that HER2/neu positive breast cancer cells are more sensitive to radiation-induced apoptosis by targeting the epidermal growth factor receptor family tyrosine kinase. We selected 466 patients with pT1-2 HER2/neu positive tumors who received adjuvant trastuzumab for primary invasive breast cancer. Patients were divided into three groups [Quadrantectomy followed by conventional radiotherapy vsQuadrantectomy followed by Intra-operative radiotherapy with electrons vsMastectomy without radiotherapy]. After a median follow-up of 52 months, the 5-year cumulative incidence of locoregional recurrence (LRR) was 1.9%, 11.5% and 5.0% respectively ( p

Original languageEnglish
Pages (from-to)856-862
Number of pages7
Issue number5
Publication statusPublished - Oct 2013


  • Breast cancer
  • HER2/neu
  • Locoregional recurrence
  • Radiation therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Locoregional recurrence in patients with HER2 positive breast cancer'. Together they form a unique fingerprint.

Cite this